Read more:
Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh